Abstracts tagged "Effectiveness"

Abstract Number: 1832 • ACR Convergence 2021
Secukinumab Therapy in Biologic-naïve vs. Biologic-experienced Patients: Real-world Effectiveness, Persistence and Safety Results from the Rheumatic Diseases Portuguese Registry
Soraia Azevedo¹, Jose Tavares-Costa², Pedro Laires³, Salomé Garcia⁴, Patricia Nero⁵, Jorge Pestana⁶, Joana Martins-Martinho⁷, Ana Bento Silva⁸, Joana Rodrigues⁹, Graca Sequeira¹⁰, Emanuel Costa¹¹, Filipe Cunha Santos¹², Carolina Furtado¹³, Bernardo Santos¹⁴, Ana Raposo¹⁵, Liliana Saraiva¹⁶, Beatriz Samões¹⁷, Filipe Barcelos¹⁸, Maria José Santos⁶ and Helena Santos¹⁹, ¹Unidade Local de Saude do Alto Minho, Ponte de lima, Portugal, ²Rheumatology Department - Unidade Local de Saude do Alto Minho, Ponte de Lima, Portugal, ³Novartis Portugal / ENSP – NOVA University of Lisbon, Lisbon, Portugal, ⁴Rheumatology Department, Centro Hospitalar Universitário de São João EPE, Porto, Portugal, ⁵CUF, TELHEIRAS, Portugal, ⁶Rheumatology Department, Hospital Garcia de Orta, Almada, Portugal, ⁷Centro Hospitalar Universitario Lisboa Norte, Lisboa, Portugal, ⁸Rheumatology Department, Hospital de Egas Moniz, Centro Hospitalar Lisboa Ocidental, Lisbon, Portugal, ⁹Rheumatology Department, ULSAM, Ponte de Lima, Portugal, ¹⁰Rheumatology Department, Centro Hospitalar Universitário do Algarve, Faro, Portugal, ¹¹Hospital de Braga, Braga, Portugal, ¹²Rheumatology Department, Local Health Unit of Guarda, Guarda, Portugal, ¹³Rheumatology Department, Hospital do Divino Espírito Santo de Ponta Delgada, Ponta Delgada, Portugal, ¹⁴Rheumatology Department, Centro Hospitalar do Baixo Vouga, Aveiro, Portugal, ¹⁵Centro Hospitalar de Trás-os-Montes e Alto Douro, Vila Real, Portugal, ¹⁶Rheumatology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, ¹⁷Rheumatology Department, Centro Hospitalar Vila Nova de Gaia, Vila Nova de Gaia, Portugal, ¹⁸Instituto Português de Reumatologia, Lisbon, Portugal, ¹⁹Portuguese Institute of Rheumatology, Lisbon, Portugal
Background/Purpose: Secukinumab has demonstrated to be efficacious for both psoriatic arthritis (PsA) and ankylosing spondylitis (AS): PASI, ACR and ASAS magnitudes of response have generally…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].